TELA Bio (TELA) Stock Price, News & Analysis

Company Overview

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key Stats

• Today's Range: $2.91 to $3.03
• 50-Day Range: $2.38 to $3.14
• 52-Week Range: $2.30 to $7.84
• Volume: 36,105 shs
• Average Volume: 192,974 shs
• Market Capitalization: $115.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.25
• Consensus Rating: Buy

TELA Bio Stock Analysis - MarketRank™

TELA Bio scored higher than 81% of companies evaluated by MarketBeat, and ranked 246th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TELA Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TELA Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TELA Bio are expected to grow in the coming year, from ($1.37) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TELA Bio is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TELA Bio is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TELA Bio has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.85% of the outstanding shares of TELA Bio have been sold short.

Short Interest Ratio / Days to Cover

TELA Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TELA Bio has recently decreased by 29.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TELA Bio does not currently pay a dividend.

Dividend Growth

TELA Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.85% of the outstanding shares of TELA Bio have been sold short.

Short Interest Ratio / Days to Cover

TELA Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TELA Bio has recently decreased by 29.83%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.19

News Sentiment

TELA Bio has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for TELA Bio this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for TELA on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

1 people have added TELA Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, TELA Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $409,995.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 6.00% of the stock of TELA Bio is held by insiders.

Percentage Held by Institutions

94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TELA Stock Analysis - Frequently Asked Questions

How have TELA shares performed this year?

TELA Bio's stock was trading at $6.62 at the beginning of the year. Since then, TELA stock has decreased by 55.6% and is now trading at $2.94.
View the best growth stocks for 2024 here.

How were TELA Bio's earnings last quarter?

TELA Bio, Inc. (NASDAQ:TELA) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.05. The business had revenue of $18.96 million for the quarter, compared to analysts' expectations of $19.10 million. TELA Bio had a negative trailing twelve-month return on equity of 556.18% and a negative net margin of 60.49%.

When did TELA Bio IPO?

TELA Bio (TELA) raised $60 million in an IPO on Friday, November 8th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are TELA Bio's major shareholders?

TELA Bio's top institutional shareholders include Stonepine Capital Management LLC (4.49%), Perkins Capital Management Inc. (0.91%), Geode Capital Management LLC (0.71%) and Landscape Capital Management L.L.C. (0.58%). Insiders that own company stock include Ew Healthcare Partners Fund 2,, Orbimed Advisors Llc, Opaleye Management Inc, Antony Koblish, Roberto Cuca, Paul Talmo and Gregory A Firestone.
View institutional ownership trends.

How do I buy shares of TELA Bio?

Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of TELA Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TELA Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 12/03/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/20/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TELA
• CUSIP: N/A
• CIK: 1561921
• Web: www.telabio.com
• Phone: 484-320-2930
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.25
• High Stock Price Target: $12.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +214.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-46,660,000.00
• Net Margins: -60.49%
• Pretax Margin: -60.49%
• Return on Equity: -556.18%
• Return on Assets: -63.13%

Debt

• Debt-to-Equity Ratio: 14.22
• Current Ratio: 2.62
• Quick Ratio: 1.81

Sales & Book Value

• Annual Sales: $58.45 million
• Price / Sales: 1.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.77 per share
• Price / Book: 3.82

Miscellaneous

• Outstanding Shares: 39,390,000
• Free Float: 37,025,000
• Market Cap: $115.81 million
• Optionable: Optionable
• Beta: 0.99